Assessing the Residual Risk: What Gaps Should New Technologies Fill?
We Recommend
Disclosures
Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:
- Consultant Fee/Honoraria/Speaker's Bureau - AstraZenca; Bayer AG; Bristol-Myers Squibb; Medtronic; Merck/Schering Plough; Boston Scientific Corporation; Daiichi-Sankyo/Elil Lilly and Company; Edwards Lifesciences; Sanofi-Aventis; Vifor; LivaNova; Impulse Dynamics; Novo Nordisk; CVRx